用选择性心肌激素激活剂omecamtiv mecarbil剂量依赖心脏缩功能的增加:这是第一次对人类进行研究
John R Teerlink1, Cyril P Clarke, Khalil G Saikali
1Section of Cardiology, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA 94121-1545, USA. john.teerlink@ucsf.edu
Lancet (London, England)
|August 23, 2011
概括
心脏肌肉蛋白激活剂Omecamtiv mecarbil在健康男性中显著改善了缩功能. 这种药物通过增强心脏收缩能力,显示出治疗心力衰竭患者的潜力.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
背景情况:
- 缩功能障碍是心力衰竭的关键因素,目前的治疗方法受到副作用的限制.
- 奥梅卡姆蒂夫 (Omecamtiv mecarbil) 是一种选择性心脏肌酶激活剂,旨在改善心脏收缩性.
研究的目的:
- 评估omecamtiv mecarbil在增强人类心脏功能的安全性,耐受性和有效性.
- 为了确定omecamtiv mecarbil的最大耐受剂量和药理动力学特征.
主要方法:
- 一项剂量升级的交叉研究,涉及34名健康男性,他们接受了omecamtiv mecarbil或安慰剂的静脉注射.
- 在整个研究过程中,对生命体征,血液样本,心电图和心声图进行了监测.
- 该研究旨在确定最大耐受剂量,并评估药理动力学和药理动力学特征.
主要成果:
- 确定最大耐受剂量为每小时0.5毫克/公斤.
- 欧梅卡姆蒂夫 (omecamtiv mecarbil) 证明了与剂量相关的缩射出时间,中风体积,分数缩短和射出分数 (p<0.0001) 的增加.
- 没有观察到高达0.625 mg/kg/小时的临床显著不良反应,心肌缺血是剂量限制性毒性.
结论:
- 首次在人体上的数据表明,omecamtiv mecarbil有效地以剂量依赖的方式增加左心室缩功能.
- 这些发现支持omecamtiv mecarbil在心力衰竭管理中的潜在临床实用性.
相关概念视频
01:26Heart Failure Drugs: Inotropic Agents
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy III: Hypertrophic Cardiomyopathy
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...